Bayer/Orion showcase results from prostate cancer challenger
Jo Taylor moves to Cello Health Communications
Biotech hopes for IPO or big pharma deal to fund phase 3
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Japanese pharma swoops after strong phase 2a results.